Table 1.

Information table for the compounds utilized in the present study

Drug	Abbreviation	Purpose	vehicle	Dose (In vivo studies)	Concentration (In vitro studies)
Estradiol Benzoate	EB	Modified Endogenous Steroid	Sesame Oil	10 μg; s.c	N/A
4,4′,4″-(4-propyl-[1H]- pyrazole-1,3,5- triyl)trisphenol	PPT	ERα Agonist	Sesame Oil (in vivo)/Punctilious ethanol (in vitro)	200 μg; s.c.	1 μM
2,3-bis(4-hydroxyphenyl)- propionitrile	DPN	ERβ Agonist	Sesame Oil	500 μg; s.c.	N/A
X isomer of the non-steroidal diphenylacrylamide made by Sandra Tobias	STX	Gq-coupled mER agonist	Propylene Glycol (in vivo)/DMSO (in vitro)	3 mg; s.c.	10 nM
(±)-1-[(3aR*,4S*,9bS*)-4-(6- Bromo-1,3-benzodioxol-5- yl)-3a,4,5,9b-tetrahydro-3H- cyclopenta[c] quinolin-8-yl]- ethanone	G-1	GPR30 Receptor Agonist	DMSO	400 μg; s.c.	3 μM
(R)-(+)-[2,3-dihydro-5- methyl-3-(4- morpholinylmethyl)pyrrolo [1, 2,3-de]-1,4-benzoxazin-6-yl]- 1-naphthalenylmethanone	WIN 55,212-2	Cannabinoid CB1/CB2 Receptor Agonist	Cremephor/Ethanol/ Saline (in vivo)/DMSO (in vitro)	0.1 mg/kg; s.c.	0.03 – 10 μM
N-(Piperidin-1-yl)-5-(4- iodophenyl)-1-(2,4- dichlorophenyl)-4-methyl- 1H-pyrazole-3-carboxamide	AM251	CB1 Receptor Antagonist	Cremephor/Ethanol/ Saline	3 mg/kg; s.c.	N/A
17β-estradiol	E2	Endogenous ER Agonist	Punctilious Ethanol	N/A	100 nM
17α-estradiol	N/A	Inactive Enantiomer	Punctilious Ethanol	N/A	100 nM
(2S)-2,6-diamino-N-[[1-(1- oxotridecyl)-2- piperidinyl]methyl]hexanami de dihydrochloride	NPC 15437	PKC Inhibitor	DMSO	N/A	30 μM
(9R,10S,12S)-2,3,9,10,11,12- hexahydro-10-hydroxy-9- methyl-1-oxo-9,12-epoxy- 1H-diindolo[1,2,3-/fg:3′,2′,1′- kl]pyrrolo[3,4- i][1,6]benzodiazocine-10- carboxylic acid, hexyl ester	KT 5720	PKA Inhibitor	DMSO	N/A	300 nM